Repozytorium UR

Clinical application of monoclonal antibodies in targeted therapy

DSpace Repository

Show simple item record

dc.contributor.author Superson, Maciej
dc.contributor.author Szmyt, Katarzyna
dc.contributor.author Szymańska, Katarzyna
dc.contributor.author Walczak, Kamil
dc.contributor.author Wnorowski, Jeremi
dc.contributor.author Zarębski, Łukasz
dc.date.accessioned 2020-01-21T13:56:06Z
dc.date.available 2020-01-21T13:56:06Z
dc.date.issued 2019
dc.identifier.citation European Journal of Clinical and Experimental Medicine T. 17, z. 4 (2019), s. 338–346 pl_PL.UTF-8
dc.identifier.issn 2544-2406
dc.identifier.uri http://repozytorium.ur.edu.pl/handle/item/5183
dc.description.abstract Introduction. Recently, monoclonal antibodies (mAbs) have become powerful human therapeutics in the diagnosis and treatment of many diseases. Drugs based on mAbs are approved for the treatment of cardiovascular, respiratory, hematology, autoimmunology, and oncology diseases. Aim. To present the current state of knowledge about the application of mAbs in the therapy of various diseases such as cancer, autoimmune and Alzheimer’s diseases. Material and methods. We conducted a thorough review of the scientific literature from the following databases: EBSCO, PubMed, Science Direct, and Springer Link. Results. Currently, the Food and Drug Administration (FDA) has approved more than 50 therapeutic mAbs which are applied in various clinical trials. Action of mAb are based on various mechanisms, including directly targeting the cells, modifying the host response, recognizing and degrading molecules as well as delivering cytotoxic moieties. Conclusion. Despite some limitations including side effects, and therapeutic challenges, monoclonal antibodies are an attractive option for the development of new therapies and molecular drug targets against a wide range of common diseases due to their specificity and flexibility. MAbs are considered as a great hope for medicine, and effective and safe drugs in the treatment of various diseases. pl_PL.UTF-8
dc.language.iso eng pl_PL.UTF-8
dc.publisher Wydawnictwo Uniwersytetu Rzeszowskiego pl_PL.UTF-8
dc.rights Attribution-NonCommercial-NoDerivatives 4.0 Międzynarodowe *
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/ *
dc.subject cancer pl_PL.UTF-8
dc.subject inflammatory bowel diseases pl_PL.UTF-8
dc.subject Alzheimer’s disease pl_PL.UTF-8
dc.subject immunotherapy pl_PL.UTF-8
dc.subject targeted therapy pl_PL.UTF-8
dc.title Clinical application of monoclonal antibodies in targeted therapy pl_PL.UTF-8
dc.type report pl_PL.UTF-8
dc.identifier.doi 10.15584/ejcem.2019.4.9
dc.identifier.eissn 2544-1361


Files in this item

The following license files are associated with this item:

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Międzynarodowe Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Międzynarodowe

Search DSpace


Browse

My Account

Statistics

Informacje